CDK2 and cancer: Cyclin E1 deletion emerged as the leading candidate suppressing cell proliferation in Rb-knockout cancer cells (Fig. 5a), corroborating that CDK2 activation drives cell-cycle entry in the absence of CDK4/6 activity.